for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

BRIEF-Bristol-Myers says ‍FDA approves Opdivo(Nivolumab) injection for intravenous use in certain patients

Sept 22 (Reuters) - Bristol-myers Squibb Co :

* Bristol-Myers Squibb’S Opdivo (Nivolumab) receives FDA approval for the treatment of Hepatocellular Carcinoma patients previously treated with Sorafenib

* U.S. FDA approved Opdivo (Nivolumab) injection for intravenous use for treatment of patients with HCC previously treated with Sorafenib Source text for Eikon: Further company coverage:

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up